E149 844
References
[1]
Cordeiro Feijoo ER, Sivaraman A, Barret E, et al. Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional out- comes. Eur Urol 2016;69:214–20.
[2]
Valerio M, Cerantola Y, Eggener SE, et al. New and established technology in focal ablation of the prostate: a systematic review. Eur Urol 2017;71:17–34.
[3]
Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007;178:2260–7.
[4]
van den Bos W, Muller BG, Ahmed H, et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol 2014;65:1078–83.
[5]
Donaldson IA, Alonzi R, Barratt D, et al. Focal therapy: patients, interventions, and outcomes—a report from a consensus meeting. Eur Urol 2015;67:771–7.
[6]
Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 2002;168:1994–9.
[7]
Sivaraman A, Barret E. Focal therapy for prostate cancer: an ‘‘a` la carte’’ approach. Eur Urol 2016;69:973–5.Arjun Sivaraman
a
Eric Barret
b,
*
a
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer
Center, New York, NY, USA
b
Department of Urology, Institute Mutualiste Monstouris, Paris, France
*Corresponding author. Department of Urology, Institut Mutualist
Montsouris, Universite´ Paris-Descartes, 42 Boulevard Jourdan,
75674 Paris Cedex 14, France. Tel. +33 1 56616619; Fax: +33 1 56616637.
E-mail address:
eric.barret@imm.fr(E. Barret).
January 19, 2017
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) e 1 4 8 – e 1 4 9
e149